Notice of Annual General Meeting
London, United Kingdom – 23rd February 2022
Dear Shareholder,
I am pleased to be writing to you with details of a General Meeting (“GM”) of the Company which we are holding at 40-46 Nestor Drive, Meadowbrook, 4131 QLD, Australia on 14 March 2022 at 9pm (Greenwich Mean Time) / 7am (Australian Eastern Standard Time) on 15 March 2022.
The formal notice of the GM is set out on pages 4 and 5 of the document.
If you would like to vote on the resolutions but cannot come to the GM, please fill in the proxy form sent to you with this notice and return it to our registrars as soon as possible. Alternatively, you may appoint a proxy electronically, if you hold your shares in CREST, through the CREST system. The registrars must receive your proxy appointment by 9pm (Greenwich Mean Time) on 12 March 2022.
An ordinary resolution and a special resolution (the “Resolutions”) are proposed in order to facilitate the Company’s ability to raise funds going forward.
Share authorities
Members are being asked to grant the Company a share authority of 350,000,000 ordinary shares of £0.01 each. This share authority will enable the Company to effectively undertake any necessary capital raising and operate the business as the Company sees fit.
Further information in relation to the use of this share authority is set out in the explanatory notes to the resolutions.
Business of the meeting
Explanatory notes on the business to be considered at this GM appear on page 8 of this document.
Future scrip dividend policy
The approval of the proposed share authorities by the shareholders of the Company would provide the board with the scope and option to consider the introduction of a scrip dividend policy in future to shareholders.
Recommendation
The board considers that all the resolutions to be put to the meeting are in the best interests of the Company and its shareholders as a whole. Your board will be voting in favour of them and unanimously recommends that you do so as well.
About Rapid Nutrition
Dedicated to the development and distribution of premium, science-based health and wellness brands across the globe, Rapid Nutrition shares a wealth of award-winning products with consumers who are passionate about innovations that are “made by nature, refined by science.” Rapid Nutrition’s first-class scientific team matches the experience of its management team to keep both the company and consumers on top of the latest industry trends and developments, while aligning with industry leaders worldwide to deliver effective supplements and solutions. Rapid Nutrition aims to be the supplier of choice globally by offering premium brands with the highest-quality ingredients to deliver maximum results.
For more information, please visit http://rnplc.com
Investor Relations Contact:
Disclaimer
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and or otherwise that involve risks, uncertainties and assumptions that could cause Rapid Nutrition PLCs actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. Rapid Nutrition PLC has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Rapid Nutrition PLC undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
This media information does not constitute an offer to sell, or a solicitation of an offer to buy, any securities. This information does not constitute an offering prospectus within the meaning within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 of June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71 or a listing prospectus within the meaning of the listing rules of the Euronext Exchange or OTC Markets. The media release is in accordance with International Reporting Standard: Rule 12g3-2(b) under the Securities Exchange Act ('Rule 12g3-2(b)') permits non-U.S. companies with securities listed primarily on a Qualified Foreign Exchange to make publicly available to U.S investors in English the same information that is made publicly available in their home countries as an alternative to SEC reporting Exchange Act Rule 12g3-2(b).